United Therapeutics Co. (NASDAQ:UTHR) CFO Sells $2,794,367.04 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $358.62, for a total value of $2,794,367.04. Following the transaction, the chief financial officer now owns 4,802 shares of the company’s stock, valued at approximately $1,722,093.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The shares were sold at an average price of $354.04, for a total value of $2,760,095.84.
• On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82.
• On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45.

United Therapeutics Price Performance

Shares of UTHR traded down $0.52 during mid-day trading on Tuesday, reaching $357.83. 202,142 shares of the stock traded hands, compared to its average volume of 484,764. The company has a market cap of $15.87 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The firm has a fifty day moving average price of $342.59 and a 200 day moving average price of $296.92. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.24 earnings per share. As a group, equities research analysts predict that United Therapeutics Co. will post 24.71 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the stock. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the second quarter worth approximately $30,000. Innealta Capital LLC bought a new position in United Therapeutics during the second quarter valued at approximately $33,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the first quarter worth approximately $32,000. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on UTHR shares. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. UBS Group lifted their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Jefferies Financial Group raised their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.